HLF HERBALIFE LTD. Insider Trading

Director Sophie L'Helias buys 1,200 HLF shares at $11.31; stock down 44.2% from 52-week high, but insider's prior 2 HLF buys showed 90-day gains of +53.7% and +48.3%.

Sophie L'Helias purchased 1,200 shares at $11.31 on 2026-06-04, increasing her holdings from 78,682 to 79,882 shares (+1.5%). This is her third open-market purchase at HLF; her prior two buys at this ticker (2025-12-01 and 2025-11-26) each generated positive 90-day returns of +53.7% and +48.3%, demonstrating a consistent pattern of well-timed entry points. The current price of $11.39 is 44.2% below the 52-week high of $20.40 and down 30.0% over the past 30 days, creating a materially depressed valuation backdrop. Her cross-ticker track record shows 100% win rate with an average 90-day return of +51.0% across 2 prior buys, suggesting consistent decision-making discipline; this transaction extends that pattern at a ticker where she has already demonstrated twice that her buys preceded substantial recovery.

HLF COO Troy Hicks sold 48,377 shares ($619.6K) in 2 transactions; post-sale holdings 9,706 shares (-83.3%)

Troy Hicks, HLF's Chief Operating Officer, executed 2 separate sales totaling 48,377 shares for $619,555.55, reducing his holdings by 83.3% from 58,083 to 9,706 shares. The sales occurred on 2026-05-18 and 2026-05-19 at prices of $12.93 and $12.32 respectively, near the current price of $12.57 and well below the 52-week high of $20.40. The near-complete divestment by a senior executive warrants investor attention, particularly given the stock's steep declines: -26.0% over 30 days and -35.8% over 90 days. HLF's fundamentals show modest annual revenue growth of +0.9% with a P/E of 5.44, providing limited context for what drove the timing and magnitude of this liquidation.

Chief Commercial Officer Frank Lamberti sells 142,919 shares worth $1.93M—his first open-market transaction.

Frank Lamberti, Chief Commercial Officer of Herbalife, executed his first open-market stock sales, disposing of nearly 79% of his shareholding across two trades. The stock is trading well below its 52-week high and has declined over the recent 90-day period, creating a context where an operational executive's decision to sell the majority of his holdings stands out. Herbalife remains profitable with modest revenue growth and trades at a notably low valuation multiple, yet Lamberti's sale in this environment—rather than buying into the weakness—marks a clear shift from his prior three-year pattern of stock-compensation transactions only. While the absolute dollar value of the sale exceeds routine thresholds, the timing and scale of the disposition (nearly four-fifths of his position) warrant closer attention to whether this reflects a broader shift in officer sentiment toward the stock or company outlook.

Director L'Helias Sophie buys 1,200 shares of HLF across 2 transactions totaling $15,448.00 at $12.87 blended avg

L'Helias Sophie purchased 1,200 shares across two separate transactions on 2025-11-26 and 2025-12-01 at prices of $13.22 and $12.70 respectively, bringing total holdings to 66,803 shares. The purchases occurred in a context where HLF trades near its 52-week high at $12.63 current price (within 5.3% of the $13.34 peak), following a substantial 57.9% gain over the prior 30 days. The company shows modest fundamentals with a 4.06 P/E ratio and recent quarterly net income of $43.2M against revenue of $1.3B, though annual revenue growth stands at -1.4%. This modest-sized addition to an already substantial director position warrants investor attention to potential shifts in management sentiment, though the magnitude remains incremental relative to the director's existing 65.6K share base.

Director Cloud Lynda buys 17,000 HLF shares at $8.97; holdings surge 77.8% to 38,857 shares

Cloud Lynda, a director at Herbalife, purchased 17,000 shares at $8.97 on 2025-11-18, increasing her holdings by 77.8% from 21,857 to 38,857 shares—a substantial accumulation in absolute terms and percentage. The purchase price of $8.97 sits 11.0% below the 52-week high of $10.83 and reflects a rebound context: the stock is up 10.9% over the preceding 30 days, though down 1.0% over 90 days. The company's fundamentals show a P/E of 3.10 against $1.3B in quarterly revenue and $43.2M net income, with annual revenue declining 1.4% year-over-year. This insider buy represents a meaningful personal stake increase at a price-point closer to the lower end of the recent range, occurring as the stock recovers from a softer 90-day trend.

Director Mendoza buys 3,143 shares of HLF at $7.50; holds 170,000 shares post-transaction, extending recent buying pattern.

Mendoza purchased 3,143 shares at $7.50 on 2025-06-05, following a buy on 2025-05-22 and adding to a position that now totals 170,000 shares. The stock has risen 17.8% over 30 days but trades 36.5% below its 52-week high of $12.49, currently at $7.93. Reviewing his prior HLF trades, Mendoza's timing record at this ticker has been mixed: 0 of 3 measurable prior buys resulted in positive 90-day returns, with a prior buy on 2024-11-08 experiencing a 90-day loss of -36.8%. The company trades at a P/E of 2.88 with $1.2B in quarterly revenue but faces -1.4% annual revenue growth. The repeated purchases at depressed levels within two weeks suggest sustained accumulation, though the absence of positive longer-term outcomes on his prior HLF purchases warrants investor attention to whether current valuations represent genuine opportunity or persistence without validation.

Director Mendoza buys 5,000 HLF shares at $6.75; stock down 46.7% from 52-week high, P/E 2.42.

Director Juan Miguel Mendoza purchased 5,000 shares of Herbalife at $6.75 on 2025-05-22, increasing his holdings to 166,857 shares, a 3.1% addition. The purchase occurs with the stock trading at $6.66 currently, down 46.7% from its 52-week high of $12.49, and the company exhibits a low valuation multiple (P/E 2.42) alongside modest near-term momentum (+1.8% over 30 days, -19.9% over 90 days). However, his prior trades at HLF show mixed outcomes: two completed 90-day measurement windows both returned negative (90d returns of -36.8% and -33.8%), and across his cross-ticker buy history, the 90-day win rate stands at 42.86% with an average 90-day return of -3.2%, indicating a track record of timing challenges. This recent buy follows a pattern of repeated accumulation at this ticker (5 prior trades in less than 7 months), which warrants assessment of whether the insider sees fundamental value or is continuing a pattern of acquisitions that have not delivered positive returns on his prior similar-period holdings.

Director Mendoza buys 5,000 HLF shares at $6.73; stock now $6.86 but -45.1% from 52-week high

Mendoza Juan Miguel (Director) purchased 5,000 shares at $6.73 on 2025-05-02, increasing holdings to 161,857 shares (a 3.2% addition to his pre-transaction position). The transaction occurs as HLF trades -45.1% from its 52-week high of $12.49, with the stock down 17.0% over the prior 30 days despite a 26.8% 90-day gain. Mendoza's same-ticker history at HLF shows a mixed pattern: his two most recent purchases (2025-03-04 and 2025-02-27) have posted near-term gains of 5.8% and 3.9% respectively, but his three prior HLF acquisitions in November 2024 all resulted in substantial negative 90-day returns (-36.8%, -33.8%, -31.6%), with 0 of 3 being well-timed at the 90-day mark. The company fundamentals show contraction (annual revenue growth of -1.4% year-over-year) and a valuation of 2.49 P/E on $50.4M net income against $1.2B quarterly revenue, suggesting limited earnings cushion relative to size.

Director Mendoza buys 2,500 HLF shares at $8.00; holds 135,000 post-transaction. Stock at $8.82, down 29.4% from 52-week high.

Mendoza purchased 2,500 shares at $8.00 on 2025-03-04, adding to a substantial existing position of 132,500 shares. The stock has recovered strongly in the near term (+63.6% over 30 days) but remains sharply depressed relative to its 52-week high of $12.49 (-29.4%). Notably, his prior trades at HLF show a poor track record: of 4 prior measurable same-ticker purchases, only 1 generated a positive 90-day return, with an average 90-day outcome of -25.6% loss across those completed transactions. His cross-ticker track record is similarly weak, averaging -3.2% over 90 days with a 42.86% win rate. The timing of this purchase—after the stock has already staged a 63.6% month-over-month rebound—suggests accumulation at a point where the recovery may already be priced in.

Director Mendoza buys 5,000 HLF shares at $8.25 on 2025-02-27; stock now at $8.11, -35.1% from 52-week high.

Mendoza Juan Miguel, a Director, purchased 5,000 shares of Herbalife at $8.25 per share on 2025-02-27, boosting his holdings by 3.9% to 132,500 shares total. The transaction occurs while the stock trades at $8.11 current price, down 35.1% from its 52-week high of $12.49, though up 48.5% over the prior 30 days. His prior five purchases at HLF show mixed timing: only 1 of 5 achieved positive 90-day returns (the September 2024 buy returned +12.0%), while the most recent November 2024 buys experienced 90-day declines ranging from -31.6% to -36.8%, indicating difficulty capturing upside at this ticker. Against the company's weak fundamentals—annual revenue declined 1.4% year-over-year to $1.2B with a minimal P/E of 4.14—the transaction adds to an established pattern of accumulation that has not generated consistent positive returns.